Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00349453
Recruitment Status : Completed
First Posted : July 7, 2006
Last Update Posted : December 12, 2011
Sponsor:
Information provided by (Responsible Party):
Lipomed

Tracking Information
First Submitted Date  ICMJE July 6, 2006
First Posted Date  ICMJE July 7, 2006
Last Update Posted Date December 12, 2011
Study Start Date  ICMJE March 2005
Actual Primary Completion Date May 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 16, 2009)
  • Liver Iron Concentration (LIC) by SQUID [ Time Frame: Yearly ]
  • Long-term safety profile [ Time Frame: Long-term ]
Original Primary Outcome Measures  ICMJE
 (submitted: July 6, 2006)
  • Liver Iron Concentration (LIC) by SQUID at yearly control visits
  • Long-term safety profile
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 16, 2009)
  • Serum ferritin [ Time Frame: At quarterly control visits ]
  • Urinary Iron Excretion (UIE) [ Time Frame: At six-monthly control visits ]
  • Heart iron content (optional) by MRI T2* and MRI SIR [ Time Frame: Yearly ]
Original Secondary Outcome Measures  ICMJE
 (submitted: July 6, 2006)
  • Serum ferritin at quarterly control visits
  • Urinary Iron Excretion (UIE) at six-monthly control visits
  • Heart iron content (optional) by MRI T2* and MRI SIR at yearly control visits
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Official Title  ICMJE Retrospective and Prospective Multicenter Study Using Deferiprone (L1) Alone or in Combination With Desferrioxamine for the Treatment of Iron Overload in Transfusion-dependent Patients
Brief Summary Systematical (retro- and prospective) investigation of the long-term safety (toxicity assessment according to CTCAE v3.0) and efficacy of deferiprone either given alone or in combination with desferrioxamine
Detailed Description

Patients with refractory anemias requiring regular blood transfusions accumulate iron at the rate of approximately 0.5 mg/kg/day, which may lead to serious organ toxicity, e.g. to the heart, liver and endocrine organs. The human body has no active mechanism for the excretion of excess iron. Therefore multiply transfused patients will develop a secondary hemosiderosis, if excess iron is not excreted by a chelating agent. Symptoms of iron-overload occur when body iron stores reach 10-20 g. At higher levels severe, even fatal complications, particularly cardiac failure, may develop.

Desferrioxamine (DFO, Desferal) is the established and commonly used iron-chelating drug, but is expensive and must be given by slow subcutaneous or intravenous infusion for 8-12 hours a day during 5-7 days weekly at a dosage of 40-50 mg/kg body weight/day. This often leads to failure of compliance of the patient and therefore to inefficient iron chelation. Further, some patients are hypersensitive to desferrioxamine and others suffer from toxicity, e.g. to the ears or eyes.

Deferiprone (L1; CP20; 1,2 dimethyl-3-hydroxypyrid-4-one) is an orally active iron chelator investigated in various clinical trials since 1987. Dosages of 75 - 100 mg/kg body weight/day of L1 have been considered effective to maintain stable iron balance (urinary iron excretion of 0.5 mg/kg/day) and to reduce serum ferritin levels between 6% and 25% within one year of treatment in iron-overloaded thalassemic patients. There exists long-term experience with patients who have received deferiprone continuously for more than 10 years so far. The main side effects encountered during a deferiprone therapy are arthropathy, gastrointestinal symptoms, headache, and mild zinc deficiency. These adverse reactions are usually reversed on reducing the dose or discontinuing the drug. Except for severe joint symptoms in few patients, most of the subjects in different clinical trials have been able to continue with L1 therapy for a long term. The most severe, but rare complication following administration of deferiprone is agranulocytosis or neutropenia.

A new treatment regimen combining deferiprone with desferrioxamine is currently being investigated in many countries. Preliminary data have demonstrated that the combined use of both drugs is highly active showing an additive or even synergistic effect (significant decrease of serum ferritin and hepatic iron content, increase of urinary iron excretion). This synergism could be explained by the different mode of action of the two drugs. It could be demonstrated that patients who were not sufficiently chelated with desferrioxamine or deferiprone, could achieve a negative iron balance with the combination treatment of both drugs. The combined regimen was generally well tolerated. It has been speculated that the individual toxicity profile of both drugs can be positively influenced by the simultaneous administration of L1 and DFO. The daily treatment with L1 tablets combined with at least twice a week administration of parenteral desferrioxamine is more patient-convenient and therefore may enhance the patient's compliance.

The primary aim of this study is to systematically investigate the long-term safety (toxicity assessment according to CTCAE v3.0) of deferiprone either given alone or in combination with desferrioxamine. Further, in patients agreeing to perform annual SQUID analysis of the liver, the annual change of liver iron concentration (LIC) will be examined for four years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hemochromatosis
Intervention  ICMJE
  • Drug: Deferiprone (L1)
    50-100 mg/kg body weight daily
  • Drug: Deferiprone (L1)
    75 mg/kg body weight daily
  • Drug: Desferrioxamine
    35-50 mg/kg body weight on 2 or more days per week
Study Arms  ICMJE
  • Experimental: Deferiprone (L1) monotherapy
    Deferiprone (L1) monotherapy
    Intervention: Drug: Deferiprone (L1)
  • Experimental: Combination therapy
    Deferiprone (L1) and desferrioxamine combination treatment
    Interventions:
    • Drug: Deferiprone (L1)
    • Drug: Desferrioxamine
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 16, 2009)
24
Original Enrollment  ICMJE
 (submitted: July 6, 2006)
30
Actual Study Completion Date  ICMJE May 2011
Actual Primary Completion Date May 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Iron overloaded male or female patients with primary or secondary hemochromatosis
  • Age: 4 years and older
  • Patients with desferrioxamine toxicity or allergy (e.g. visual or hearing defects, bone abnormalities, reactions at injection site)
  • Patients unable or unwilling to comply satisfactorily with regular desferrioxamine administration on 5-7 days/week
  • Combination treatment: patients not sufficiently chelated with desferrioxamine or deferiprone monotherapy
  • Patients must be willing to undergo routine screening including medical history, physical examination and hematology, biochemistry and other laboratory tests
  • Written informed consent

Exclusion Criteria:

  • Children under 4 years of age
  • Female and male of reproductive age, sexually active but not taking adequate contraceptive precaution
  • Woman who are pregnant or breast-feeding
  • Patients with HIV
  • Patients with active hepatitis requiring treatment
  • Patients with severe hepatic failure, cirrhosis
  • Patients with neutropenia (neutrophils less than 1.5 exp9/l, MDS: less than 0.5 exp9/l)
  • Patients with thrombocytopenia (platelets less than 100 exp9/l, MDS: less than 20 exp9/l)
  • Patients with decompensated heart failure (LVEF less than 40% or patients under continuous cardiac medication)
  • Patients with severe renal failure
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 4 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00349453
Other Study ID Numbers  ICMJE DF-2/CH
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Lipomed
Study Sponsor  ICMJE Lipomed
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Petrign FG Töndury, MD
Principal Investigator: Markus Schmugge Liner, MD University Children's Hospital, Zurich
PRS Account Lipomed
Verification Date December 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP